Skip to main content

Month: June 2022

Coop Pank AS results for May 2022

Coop Pank AS results for May 2022 Coop Pank’s financial results in May 2022:In May, number of the bank’s clients increased by 2900 and number of active clients increased by 1700. By the end of the month number of clients reached 128,300 and number of active clients reached 55,400. Over the year, customer base has grown by 31%. Volume of the bank’s customer deposits increased by 28 million euros, reaching 1.19 billion euros by the end of month. Deposits of corporate customers increased by 25 million and deposits of private customers remained at the same level as in April. The volume of deposits attracted from international platforms increased by 4 million euros. Over the year, volume of bank deposits has grown by 36%. The bank’s loan portfolio increased by 38 million euros over the month and reached 1.1 billion euros...

Continue reading

Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting

Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatment Updated data from phase III CLL14 study of Venclexta®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) showed more than 60% of previously untreated people with chronic lymphocytic leukaemia remained in remission five years after starting treatment[1] Final analysis of phase III GALLIUM study showed meaningful improvement in progression-free survival was maintained with Gazyva/Gazyvaro plus chemotherapy in people with previously untreated follicular lymphoma after eight years of follow-up[2]Basel, 10 June 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today...

Continue reading

Santhera Reports 2021 Annual Results

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST, 13:30 BST, 08:30 EDT. Details are at the end of this statement.Revenue from contracts with customers of CHF -1.6 million (2020: CHF 15.0 million) Operating result of CHF –56.9 million (2020: CHF –53.1 million) and net result of CHF –55.5 million (2020: CHF -67.7 million) Cash and cash equivalents of CHF 21.2 million as of December 31, 2021 Recent financing is expected to provide funding through Q1-2023 or up to the earliest expected approval time for vamorolone in the U.S. Key regulatory milestones reached with vamorolone; rolling submission to the U.S. FDA to be completed by end of June 2022Pratteln, Switzerland, June 10, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces the Company’s audited financial results for...

Continue reading

Molecular Partners Announces Participation in Scientific Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2022 (GLOBE NEWSWIRE) —  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its team will participate in the European Hematology Association (EHA) Conference as well as other conferences in June. In addition, Novartis, the global license owner of ensovibep, will present preclinical data from the anti-SARS-CoV-2 program. Conferences Details:Poster; European Hematology Association (EHA) ConferenceTitle: MP0533, a New Multispecific DARPin CD3 Engager Targeting Three Tumor Associated Antigens, Induces Specific T-cell Activation and AML Tumor Killing in vivo June 9-12, ViennaPoster (Novartis); American Society for Microbiology...

Continue reading

Flow Capital Announces Proposed Preferred Share Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES TORONTO, June 09, 2022 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV: FW) (“Flow Capital” or the “Company“) is pleased to announce a proposed offering of up to 1,811,666 newly created Series I Class A Preferred Shares (the “Series I Class A Preferred Shares“) on a private placement basis at a price of $3.00 per Series I Class A Preferred Share, for gross proceeds of approximately $5,435,000 (the “Offering“). The Series I Class A Preferred Shares, which are non-voting and non-convertible except in each case in certain limited circumstances, carry a cumulative dividend of 9.2%, paid quarterly, and are redeemable by the Company six years following the initial issuance date. In addition, a...

Continue reading

Cindy Hill-Finnie Promoted to First Fed Board Chair

Cindy Hill-Finnie Promoted to First Fed Board Chair Cindy Hill-Finnie (Chair) and Jennifer Zaccardo (Vice Chair)PORT ANGELES, Wash., June 09, 2022 (GLOBE NEWSWIRE) — First Fed Bank, subsidiary of First Northwest Bancorp (NASDAQ: FNWB) (“Company”), today announced that Cindy Hill-Finnie has been promoted from Vice Chair to Board Chair. Hill-Finnie is the first woman to hold this leadership role on the Board of Directors. Jennifer Zaccardo has been promoted to Vice Chair. “Cindy is a respected leader with extensive experience in financial management, sales, business development, and community service. She has demonstrated her leadership skills during her past 10 years on the board, most recently as Vice Chair. Cindy was a natural choice to become our new Board Chair,” said Matt Deines, President and CEO of First Fed Bank and...

Continue reading

Goldgroup Closes First Tranche of Non-Brokered Private Placement

VANCOUVER, British Columbia, June 09, 2022 (GLOBE NEWSWIRE) — Goldgroup Mining Inc. (“Goldgroup” or the “Company”) (TSX:GGA, OTC:GGAZF, BMV SIX:GGAN.MX) is pleased to announce that a first tranche of the upsized non-brokered private placement of units (“Units”) announced on April 19, 2022 and June 3, 2022 (the “Private Placement”) has been completed. Pursuant to the first tranche of the Private Placement, the Company issued 17,442,857 Units at a price ‎of $0.035 per Unit, for aggregate gross proceeds of approximately $610,500. Each Unit consists of one ‎common share of the Company (a “Share”) and one common share purchase warrant (a “Warrant”), with each Warrant exercisable to purchase one Share at a ‎price of $0.05 per Share until June 9, 2025. All securities issued in connection with the Private Placement are subject to a statutory...

Continue reading

Calavo Growers, Inc. Names Shawn Munsell CFO

Calavo Growers Names Shawn Munsell CFO Shawn Munsell joins Calavo on June 20 as its new CFO.SANTA PAULA, Calif., June 09, 2022 (GLOBE NEWSWIRE) — Calavo Growers, Inc. (Nasdaq-GS: CVGW), a global avocado-industry leader and provider of value-added fresh food, today announced that Shawn Munsell has been appointed Chief Financial Officer effective June 20. Prior to joining Calavo, Mr. Munsell led the finance and accounting functions for Tyson Foods’ chicken segment, with fiscal 2021 revenues of $14 billion, as Senior Vice President of Finance and Accounting. Previously, he served as Tyson’s Treasurer. Prior to Tyson, Mr. Munsell was with CF Industries, serving in a variety of roles with progressive responsibility for the nitrogen products manufacturer. “We’re thrilled to have Shawn Munsell join the Calavo team,” said Brian W. Kocher,...

Continue reading

AMD Details Strategy to Drive Next Phase of Growth Across $300 Billion Market for High-Performance and Adaptive Computing Solutions

AMD unveils next-generation hardware and software roadmaps, expanded product portfolio addressing new markets, and strategies to accelerate data center growth and deliver pervasive AI leadership SANTA CLARA, Calif., June 09, 2022 (GLOBE NEWSWIRE) — Today at its Financial Analyst Day, AMD (NASDAQ: AMD) outlined its strategy to deliver its next phase of growth driven by the company’s expanded portfolio of high-performance and adaptive computing products spanning the data center, embedded, client, and gaming markets. “From the cloud and PCs to communications and intelligent endpoints, AMD’s high-performance and adaptive computing solutions play an increasingly larger role in shaping the capabilities of nearly every service and product defining the future of computing today,” said Dr. Lisa Su, AMD chair and CEO. “The close of our transformational...

Continue reading

Titan Medical Reports Voting Results From Annual and Special Meeting of Shareholders

TORONTO, June 09, 2022 (GLOBE NEWSWIRE) — Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced the voting results form the company’s Annual and Special Meeting of its shareholders held on Wednesday June 8, 2022. All of management’s nominees for election were duly elected as directors of the company by the shareholders presented or represented by proxy at the meeting. A total of 54,760,905 of the 111,202,690 common shares outstanding, or 49.24%, were voted at the meeting. The results of the vote were reported to the meeting by Computershare, which acted as scrutineer at the meeting and were as follows:Directors Votes For % Votes Withheld %Paul Cataford 16,268,282 75.34 5,324,019 24.66Anthony...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.